UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~August~~October 2825, 2018

BIOAMBER INC.

(Exact name of registrant as specified in charter)

Delaware

001-35905

98-0601045

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1250 Rene Levesque West, Suite 4310

Montreal, Quebec, Canada H3B 4W8

(Address of principal executive office)

Registrant’s telephone number, including area code (514) 844-8000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 58.0201. ~~Departure~~Other ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~Events

On ~~August~~October 2825, 2018, ~~Kurt Briner, Robert Frost, Heinz Haller, Ellen Richstone and Kenneth Wall each resigned from the Board of Directors of~~ BioAmber Inc. ~~(the~~issued ~~“Company”),~~a ~~including~~press ~~all~~release ~~committees~~entitled ~~thereof,~~“BioAmber ~~and~~Provides Update on ~~August 29,~~Liquidation ~~2018, Raymond Land resigned from the Board and all committees thereof~~Process.” NoA ~~director~~copy ~~resigned~~of ~~because~~the ofpress ~~any~~release ~~disagreement~~is ~~with~~attached ~~the~~hereto ~~Company~~as onExhibit ~~any~~99.1 ~~matter~~and ~~relating~~is toincorporated ~~its~~herein ~~operations,~~by ~~policies or practices~~reference.

OnItem ~~August 31, 2018, Richard Eno, the Company’s chief executive officer and director, Michael Hartmann, the Company’s executive vice-president and president of BioAmber Sarnia Inc~~9.,01 ~~James~~Financial ~~Millis,~~Statements ~~the Company’s chief technology officer~~ and ~~Mario Settino, the Company’s chief financial officer, each voluntarily resigned from their offices at the Company.~~ Exhibits

A(d) ~~copy~~Exhibits ~~of the press release by the Company announcing the above-described executive changes is furnished with this Report as Exhibit 99.1.~~

Item 9.01 Financial Statements and Exhibits


Exhibit Number		Description

99.1		Press Release, dated October 25, 2018.

~~(d) Exhibits~~EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release, dated ~~August~~October 3125, 2018.

~~EXHIBIT~~SIGNATURES ~~INDEX~~

Exhibit Number		Description
99.1		Press Release, dated August 31, 2018.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOAMBER INC.

Date: October 26, 2018

/s/ Mica Arlette

Name: Mica Arlette

Title: Senior Vice President, Corporate Advisory & Restructuring, PricewaterhouseCoopers Inc.

Filing Compare · BioAmber Inc.